Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In consultation
In consultation: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Consultation end date
Consultation end date
From date
To date
Apply date filters
Type
Type
Guidance (19)
Quality standard (1)
Guidance programme
Guidance programme
HealthTech guidance (1)
Interventional procedures guidance (1)
Quality standard (1)
Technology appraisal guidance (17)
Apply filters
Showing 11 to 20 of 20
Sort by
Date
Title
Apply sorting
Guidance and quality standards in consultation
Title
Consultation
Type
Consultation end date
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
14 April 2026
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death
Draft scope consultation
Interventional procedures guidance
10 April 2026
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]
Final draft guidance
Technology appraisal guidance
9 April 2026
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]
Final draft guidance
Technology appraisal guidance
9 April 2026
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
8 April 2026
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]
Draft guidance
Technology appraisal guidance
7 April 2026
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]
Draft guidance
Technology appraisal guidance
7 April 2026
Bepirovirsen for treating chronic hepatitis B [ID6608]
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
7 April 2026
Gender Incongruence Services for Children and Young People
Topic engagement
Quality standard
2 April 2026
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
1 April 2026
Previous page
1
Current page
2
Page
2
of
2
Results per page
10
25
50
All
Back to top